Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDARS Pharmaceuticals Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.54 | -$0.37 | -$0.48 |
| Q2 2026 | 1 | -$0.51 | -$0.33 | -$0.41 |
| Q3 2026 | 1 | -$0.29 | -$0.19 | -$0.23 |
| Q4 2026 | 1 | -$0.45 | -$0.29 | -$0.36 |
| Q1 2027 | 1 | -$0.32 | -$0.20 | -$0.26 |
| Q2 2027 | 1 | $0.01 | $0.01 | $0.01 |
| Q3 2027 | 1 | $0.24 | $0.37 | $0.30 |
| Q4 2027 | 1 | -$0.02 | -$0.01 | -$0.01 |
ARS Pharmaceuticals Inc Earnings Date And Information
ARS Pharmaceuticals Inc last posted its earnings results on Monday, November 10th, 2025. The company reported $-0.52 earnings per share for the quarter, missing analysts' consensus estimates of $-0.45 by $0.07. The company had revenue of 32.50 M for the quarter and had revenue of 89.15 M for the year. ARS Pharmaceuticals Inc has generated $0 earnings per share over the last year ($0.0781 diluted earnings per share) and currently has a price-to-earnings ratio of -11.32. ARS Pharmaceuticals Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
ARS Pharmaceuticals Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/10/2025 | Q3 2025 | -$0.45 | -$0.52 | -0.07 | $28.67 M | $32.50 M |
| 08/13/2025 | Q2 2025 | -$0.41 | -$0.46 | -0.05 | $13.78 M | $15.72 M |
| 05/14/2025 | Q1 2025 | -$0.35 | -$0.35 | 0 | N/A | $7.97 M |
| 03/20/2025 | Q4 2024 | -$0.04 | $0.51 | 0.55 | N/A | $86.58 M |
| 11/13/2024 | Q3 2024 | -$0.18 | -$0.20 | -0.02 | $575.00 K | $2.07 M |
| 08/06/2024 | Q2 2024 | -$0.12 | -$0.13 | -0.01 | $1.00 M | $500.00 K |
| 05/09/2024 | Q1 2024 | -$0.11 | -$0.11 | 0 | N/A | $0 |
| 03/21/2024 | Q4 2023 | -$0.14 | -$0.07 | 0.07 | N/A | $0 |
| 11/09/2023 | Q3 2023 | -$0.18 | -$0.16 | 0.02 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.17 | -$0.18 | -0.01 | N/A | $10.00 K |
| 05/15/2023 | Q1 2023 | -$0.17 | -$0.12 | 0.05 | N/A | $20.00 K |
| 03/23/2023 | Q4 2022 | -$0.13 | -$0.15 | -0.02 | N/A | $0 |
| 09/29/2022 | Q3 2022 | N/A | -$0.07 | N/A | N/A | $189.00 K |
| 08/11/2022 | Q2 2022 | -$0.48 | -$0.06 | 0.42 | N/A | $464.00 K |
| 03/31/2022 | Q1 2022 | -$0.70 | -$0.08 | 0.62 | N/A | $663.00 K |
| 03/31/2022 | Q4 2021 | -$0.70 | -$0.67 | 0.03 | N/A | $754.00 K |
| 09/29/2021 | Q3 2021 | N/A | -$0.65 | N/A | N/A | $528.00 K |
| 06/29/2021 | Q2 2021 | N/A | -$0.70 | N/A | N/A | $2.11 M |
| 03/30/2021 | Q1 2021 | N/A | -$0.54 | N/A | N/A | $2.11 M |
| 12/29/2020 | Q4 2020 | N/A | -$0.38 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
ARS Pharmaceuticals Inc Earnings: FAQ's
The conference call for ARS Pharmaceuticals Inc's latest earnings report can be listened to online.
The conference call transcript for ARS Pharmaceuticals Inc's latest earnings report can be read online.
ARS Pharmaceuticals Inc (:SPRY) has a recorded annual revenue of $89.15 M.
ARS Pharmaceuticals Inc (:SPRY) has a recorded net income of $8.00 M.ARS Pharmaceuticals Inc has generated $0.0825 earnings per share over the last four quarters.
ARS Pharmaceuticals Inc (:SPRY) has a price-to-earnings ratio of -11.32 and price/earnings-to-growth ratio is 0.18.